Tuesday, October 19, 2021 1:47:03 PM
I don't know just how novel ENZC's methodology for discovering (patentable) immutable sites is or how valuable those sites might be (IP), but Dr. Chandra did say their process is "unique" and that no else has done it before. (That said, AI has been used in biotech going as far back as the 90s.)
The value of those immutable sites will be determined by whether or not ENZC can develop safe and effective treatments/cures, or if other pharma companies are keen on buying or licensing ENZC's IP (likely dependent on certain development milestones). Hopefully, Samsung can help ENZC expedite the arduous process to clinical trials, starting from cell line development of their mAbs through regulatory filings and IND. I don't imagine that will be done before Q2 2022, so my eyes are on ITV-1 as the nearest candidate for clinical trials, and audited financials along with application to QB as the next catalyst.
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM